AlphaMadera's AlphaVal page classifies Indivior Pharmaceuticals Inc as a Stable Earnings Power business and values it using P/Adj-EPS × Normalized Multiple, then compares the result to the current market price to flag INDV as undervalued, fairly valued, or overvalued.

What is Indivior Pharmaceuticals Inc's fair value?

Fair value for INDV comes from a P/Adj-EPS × Normalized Multiple model -- the approach AlphaVal selected for this company's Stable Earnings Power classification. The live AlphaVal page shows bear, base, and bull scenarios alongside the key assumption behind each.

How does AlphaMadera value INDV?

AlphaVal routes each company to one of ten valuation archetypes based on its business model. INDV was classified as Stable Earnings Power and is valued using P/Adj-EPS × Normalized Multiple, built from INDV's most recent reported fundamentals.

INDV - Indivior Pharmaceuticals Inc

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $48.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Moderate

Trading 37.3% above fair value

Current Price $34.85

Bear Case $21.76 37.6% downside ($21.76 - $34.85) / $34.85 = -37.6% $1.64 × 13x P/E

Fair Value $25.39 27.2% downside ($25.39 - $34.85) / $34.85 = -27.2% $1.64 × 15x P/E

Bull Case $29.01 16.7% downside ($29.01 - $34.85) / $34.85 = -16.7% $1.64 × 18x P/E

Adjust Assumptions

P/E Multiple

15.5x

Adjusted EPS

1.64$

Key Value Driver

Normalized P/E multiple (15x base case)

Terminal Value % of EV

Implied Market Multiple 21.3x

Market is pricing in (growth)

Plain-Language Summary

Applying a 15x P/E to adjusted EPS of $1.64, the base-case value is $25.39 per share.

Warnings

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples